Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer

BACKGROUND: This single-arm phase II study investigated the EGFR monoclonal antibody necitumumab plus modified FOLFOX6 (mFOLFOX6) in first-line treatment of locally advanced or metastatic colorectal cancer (mCRC). METHODS: Patients received 800-mg intravenous necitumumab (day 1; 2-week cycles), foll...

Descripción completa

Detalles Bibliográficos
Autores principales: Elez, E, Hendlisz, A, Delaunoit, T, Sastre, J, Cervantes, A, Varea, R, Chao, G, Wallin, J, Tabernero, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815776/
https://www.ncbi.nlm.nih.gov/pubmed/26766738
http://dx.doi.org/10.1038/bjc.2015.480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815776/
https://www.ncbi.nlm.nih.gov/pubmed/26766738
http://dx.doi.org/10.1038/bjc.2015.480

Ejemplares similares